Samsara BioCapital’s vTv Therapeutics VTVT Stock Holding History

Samsara BioCapital’s Portfolio VTVT Stock Details VTVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.2M	Hold	298,496	–	–	0.92%	13
2026 Q1	$11.8M	Hold	298,496	–	–	1.15%	11
2025 Q4	$11.9M	Sell	298,496 -75,965	-20%	-$2.11M	1.23%	12
2025 Q3	$8.74M	Buy	374,461 +167,677	+81%	+$2.94M	1.14%	13
2025 Q2	$3.1M	Hold	206,784	–	–	0.63%	19
2025 Q1	$3.58M	Hold	206,784	–	–	0.64%	19
2024 Q4	$2.86M	Hold	206,784	–	–	0.39%	28
2024 Q3	$2.81M	Hold	206,784	–	–	0.54%	26
2024 Q2	$3.65M	Hold	206,784	–	–	0.76%	25
2024 Q1	$4.87M	Buy	206,784 +165,896	+406%	+$2.11M	0.75%	24
2023 Q4	$470K	Hold	40,888	–	–	0.07%	34
2023 Q3	$782K	Hold	40,888	–	–	0.24%	34
2023 Q2	$1.21M	Hold	40,888	–	–	0.21%	36
2023 Q1	$1.32M	Hold	40,888	–	–	0.27%	38
2022 Q4	$1.08M	Hold	40,888	–	–	0.23%	38
2022 Q3	$1.59M	Hold	40,888	–	–	0.37%	38
2022 Q2	$1.23M	Hold	40,888	–	–	0.33%	41
2022 Q1	$1.18M	Hold	40,888	–	–	0.3%	44
2021 Q4	$1.63M	Buy	+40,888	New	+$2.2M	0.32%	40

Other funds holding VTVT

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Samsara BioCapital's VTVT Position: Q2 2026 in Review

Samsara BioCapital held its vTv Therapeutics (VTVT) position steady in Q2 2026 at 298,496 shares worth $11.2M. The position accounts for 0.92% of the portfolio, ranked #13.

Samsara BioCapital first reported a position in VTVT in Q4 2021 and has held it in 19 quarters since. The position peaked at $11.9M in Q4 2025. 45 funds tracked by Wall St. Rank hold VTVT as of Q2 2026.

Samsara BioCapital held 298,496 shares of vTv Therapeutics worth $11.2M as of Q2 2026.
Samsara BioCapital left its vTv Therapeutics share count unchanged in Q2 2026.
vTv Therapeutics made up 0.92% of Samsara BioCapital's portfolio in Q2 2026, its #13 holding.
Samsara BioCapital first reported a position in vTv Therapeutics in Q4 2021 and has held it in 19 quarters since.
Samsara BioCapital's vTv Therapeutics position peaked at $11.9M in Q4 2025.
45 funds tracked by Wall St. Rank held vTv Therapeutics as of Q2 2026.

Based on Samsara BioCapital's 13F filing for Q2 2026, filed 14 Aug 2026.